Skip to main content
Medical information Clinical review pending

Haematology Testing

Acute Myeloid Leukemia AML Cytogenetics Panel Test

The Acute Myeloid Leukemia (AML) Cytogenetics Panel Test identifies specific genetic abnormalities in blood or bone marrow cells to aid in the diagnosis, treatment planning, and prognosis of AML.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
8 mL (6 mL min.) whole blood from 2 Green Top (Sodium Heparin) tubes AND 4 mL (2 mL min.) Bone Marrow from 1 Green Top (Sodium Heparin) tube.
Results
Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. A duly filled Chromosome and FISH analysis Requisition form (Form 17) is mandatory prior to testing.
Test priceKSh 46,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Acute Myeloid Leukemia AML Cytogenetics Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected diagnosis of Acute Myeloid Leukemia (AML)
  • ✓Evaluation of unexplained fatigue, infections, bruising, or bleeding
  • ✓Risk assessment for AML
  • ✓Guiding treatment strategies for AML
  • ✓Prognosis determination in AML
02

In plain language

What this test helps you understand

This test helps in the diagnosis of AML, guides treatment decisions based on specific genetic markers, and provides prognostic information.
The Acute Myeloid Leukemia (AML) Cytogenetics Panel Test is a specialized diagnostic tool used to identify specific genetic abnormalities in patients suspected of having Acute Myeloid Leukemia (AML). Understanding these genetic changes is crucial for determining the most effective treatment strategies and for predicting patient outcomes. This test plays a significant role in the clinical management of AML, helping hematologists tailor therapies based on individual patient profiles.

This test detects specific chromosomal abnormalities associated with AML, including: - t(8;21) or LSI ETO/AML1 - inv(16) (p13q22) or t(16;16) (p13;q22) or CBFB - t(15;17) or LSI PML/RARA - t(variable;11q23); MLL gene breakapart - Comprehensive chromosome analysis for hematological malignancies

Patients exhibiting symptoms such as unexplained fatigue, frequent infections, easy bruising, or bleeding may be recommended for this test. Additionally, individuals with risk factors such as a family history of leukemia or previous chemotherapy treatments should also consider undergoing the AML Cytogenetics Panel Test.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. A duly filled Chromosome and FISH analysis Requisition form (Form 17) is mandatory prior to testing.
Sample8 mL (6 mL min.) whole blood from 2 Green Top (Sodium Heparin) tubes AND 4 mL (2 mL min.) Bone Marrow from 1 Green Top (Sodium Heparin) tube.
MethodologyCytogenetic analysis (karyotyping) and Fluorescence In Situ Hybridization (FISH) are used to detect chromosomal abnormalities.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific chromosomal abnormalities but may not identify all genetic changes associated with AML. Results must be interpreted in the context of the patient's clinical presentation and other laboratory findings.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

AML is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.
Identifying specific genetic abnormalities helps doctors choose the most effective treatment and understand the likely course of the disease.
Both a blood sample and a bone marrow sample are required for comprehensive analysis.
Samples should be shipped at a temperature of 18-22°C and must not be frozen.
Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp